Immunoglobulin M myeloma: Evaluation of molecular features and cytokine expression

Clinical Lymphoma

Volumn 5, Issue 4, 2005, Pages 285-289

  Konduri, Kartik ^a   Sahota, Surinder S ^b   Babbage, Gavin ^b   Tong, Alex W ^a   Kumar, Padmasini ^a   Newman, Joseph T ^a   Stone, Marvin J ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Osteoclast activating factor; Osteoprotegerin; Plasma cell dyscrasias; Tumor VH gene

Indexed keywords

ALKYLATING AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; ERYTHROPOIETIN; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; M PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; THALIDOMIDE;

ADULT; ANEMIA; ARTICLE; BONE ATROPHY; BONE DISEASE; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 13Q; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 13; CHROMOSOME TRANSLOCATION 14; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENOME ANALYSIS; GERMINAL CENTER; HUMAN; HYPERVISCOSITY SYNDROME; IMMUNOGLOBULIN M MYELOMA; LYMPHOCYTIC INFILTRATION; MALE; MORTALITY; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PATHOGENESIS; PLASMA CELL DYSCRASIA; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETINA VEIN OCCLUSION; RIB FRACTURE; THORAX RADIOGRAPHY; TRANSCRIPTION REGULATION; TREATMENT FAILURE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 18144379529     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.018     Document Type: Article

References (35)

1. Creyssel R, Charvillat L, Morel P, et al. Contribution a l'etude biochemique du myelome multiple et des dysproteinemies malignes. Rev Lyon Med 1956; 5:129-171.
2. MacKenzie M, Fudenberg H. Macroglobulinemia: an analysis of forty patients. Blood 1972; 39:874-889.
3. Berman H. Waldenström's macroglobulinemia with lytic osseous lesions and plasma-cell morphology. Am J Clin Pathol 1974; 63:397-402.
4. Vermess M, Pearson KD, Einstein AB, et al. Osseous manifestations of Waldenström's macroglobulinemia. Radiology 1972; 102:497-504.
5. Stein R, Ellman L, Bloch K. The clinical correlates of IgM M-components: an analysis of thirty-four patients. Am J Med Sci 1975; 269:209-216.
6. Fagiolo E. Plasmocytoma with IgM paraproteinemia: a case report. Acta Haematol 1976; 55:123-128.
7. Leb L, Grimes E, Balogh K, et al. Monoclonal macroglobulinemia with osteolytic lesions. Cancer 1977; 39:227-231.
8. Tubbs R, Hoffman G, Deodhar S, et al. IgM monoclonal gammopathy: histopathologic and clinical spectrum. Cleve Clin Q 1976; 43:217-235.
9. Zarrabi M, Stark R, Kane P, et al. IgM myeloma, a distinct entity in the spectrum of B-cell neoplasia. Am J Clin Pathol 1981; 75:1-10.
10. Takahashi K, Yamamura F, Motoyama H. IgM myeloma - its distinction from Waldenström's macroglobulinemia. Acta Pathol Jpn 1986; 36:1553-1563.
11. Kyle R, Garton J. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987; 62:719-731.
12. Haghighi B, Yanagihara R, Cornbleet P. IgM myeloma: case report with immunophenotypic profile. Am J Hematol 1998; 59:302-308.
13. Kondo H, Yokoyoma K. IgM myeloma: different features from multiple myeloma and macroglobulinemia. Eur J Hematol 1999; 63:366-368.
14. Schlesinger N, Neustadter L, Schumacher H. Lytic bone lesions as a prominent feature of Waldenström's macroglobulinemia. J Clin Rheumatol 2000; 6:150-152.
15. Dierlamm T, Laack E, Dierlamm J, et al. IgM myeloma: a report of four cases. Ann Hematol 2002; 81:136-139.
16. Chehal A, Taher A, Shamseddine A. IgM myeloma and Waldenström's macroglobulinemia: a distinct clinical feature, histology, immunophenotype and chromosomal abnormality. Clin Lab Haematol 2003; 25:187-190.
17. Kjeldsen K, Asfeldt V. Macroglobulinemia or multiple myeloma. Acta Medica Scand 1963; 174:407-413.
18. Welton J, Walker S, Sharp G, et al. Macroglobulinemia with bone destruction. Am J Med 1968; 44:280-288.
19. Case Records of the New England Journal of Medicine. N Engl J Med 1972; 287:243-248.
20. H Gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Blood 1999; 94:1070-1076.
21. Godoy-Ramirez K, Franck K, Mahdavifar S, et al. Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. J Immunol Methods 2004; 292:1-15.
22. Tong AW, Seamour B, Vukelja S, et al. Cellular immune profile of advanced cancer patients. Am J Clin Oncol 2000; 23:463-472.
23. Corbett SJ, Tomlinson IM, Sonnhammer EL, et al. Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination. J Mol Biol 1997; 270:587.
24. Sahota S, Forconi F, Ottensmeier C, et al. Typical Waldenström's macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100: 1505-1507.
25. Sahota SS. Evaluating Clonal Origins in Waldenström's Macgroglobulinemia. The Third International Workshop on Waldenström's Macroglobulinemia, Paris, France 2004; 27 (Abstract #2).
26. Avet-Loiseau H, Garand R, Lode L, et al. 14q32 Translocations discriminate IgM multiple myeloma from Waldenström's macroglobulinemia. Semin Oncol 2003; 30:153-155.
27. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
28. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor kappaB ligand (RANKL) on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003; 9:1436-1440.
29. Sezer O, Heider U, Jakob C, et al. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2OO2; 20:353-354.
30. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized and degraded by multiple myeloma cells. Blood 2002; 100:3002-3007.
31. Seidel C, Hjertner O, Abildgaar N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98:2269-2271.
32. Terpos E, Szydlo R, Apperley J, et al. Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102:1064-1069.
33. Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1α) in monoclonal gammopathy of undetermined significance (MGUS). Brit J Haematol 2004; 126:686-689.
34. Choi S, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in myeloma. Blood 2000; 96:671-675.
35. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483-2494.